Rotigotine patch is approved for market in China

Recently, the innovative drug used to treat Parkinson's disease developed by UCB has been approved by China food and Drug Administration for listing in China! Upro ® is the first patch for Parkinson's disease, which is different from the route of administration of all treatment options on the market Upro ® will provide new treatment options for Chinese patients and their families affected by this chronic disease, and help Chinese Parkinson's patients regain a comfortable and high-quality life At present, there are about 3 million Parkinson's patients in China, and it is estimated that there are more than 100000 new cases every year Most of the patients were over 60 years old, but about one tenth of them were diagnosed before 50 years old Upro ® is suitable for single drug treatment of symptoms and signs of early idiopathic Parkinson's disease (not combined with levodopa), or in combination with levodopa at all stages of the course of the disease, until the efficacy of levodopa in the late stage of the disease decreases, is unstable or fluctuates (end of dose phenomenon or "on-off" phenomenon) Approved for marketing in China, Upro ® will provide innovative solutions for Chinese patients and provide new powerful weapons for standardized treatment of Parkinson's disease in China.